diffuse glioma, H3 G34 mutant
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:0080880
Name diffuse glioma, H3 G34 mutant
Definition A histone mutated tumor that has_material_basis_in mutations in codon 34 of the H3 histone family 3A protein.
Source DiseaseOntology.org
Alt Ids
Xrefs
ICDO:9385/3
Path disease disease of cellular proliferation cancer cell type cancer high grade glioma histone mutated tumor diffuse glioma, H3 G34 mutant

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04908176 Phase I Avapritinib + Midazolam A Drug-drug Interaction Study of Avapritinib and Midazolam Completed USA 0
NCT05429502 Phase Ib/II Ribociclib + Temozolomide + Topotecan Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors Terminated USA | ITA | GBR | DEU 0
NCT05457959 Phase I Nivolumab + Poly ICLC Ipilimumab + Nivolumab + Poly ICLC DC tumor cell lysate vaccine + Poly ICLC DC tumor cell lysate vaccine + Ipilimumab + Nivolumab + Poly ICLC DC tumor cell lysate vaccine + Nivolumab + Poly ICLC Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant Withdrawn USA 0
NCT05843253 Phase II Ribociclib + Temozolomide Everolimus + Ribociclib Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant Recruiting USA | NZL | NLD | GBR | DEU | CAN | AUS 0
NCT06342908 Phase I Neoantigen-targeted ppDC Poly ICLC A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma Recruiting USA 0
NCT06413706 Phase II Abemaciclib + Temozolomide Temozolomide A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy Recruiting USA | ROU | NLD | ITA | FRA | ESP | DNK | BEL | AUS 1
NCT06630260 Phase Ib/II Defactinib + RO5126766 + Temozolomide Defactinib + RO5126766 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours (5G-RUBY) Recruiting GBR 0
NCT06632236 Phase I Amivantamab-vmjw 5G-EMERALD: Amivantamab in Malignant Brain Tumours (5G-EMERALD) Recruiting GBR 0
NCT06894979 Phase I AZD1390 Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma Recruiting USA 0
NCT06896110 Phase I Azacitidine + Nivolumab Intrathecal Azacitidine and Nivolumab in Patients with Recurrent High-grade Glioma Enrolling by invitation USA 0
NCT06914479 Phase I AdV-Flt3L + AdV-HSV1-TK + Valganciclovir Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors Not yet recruiting USA 0
NCT07223034 Phase I lutetium Lu 177 vipivotide tetraxetan + Temozolomide A Study of 177Lu-PSMA-617 in People With Gliomas Recruiting USA 0